✦ LIBER ✦

Open-Label Study of Pemetrexed Alone or in Combination with Cisplatin for the Treatment of Patients with Peritoneal Mesothelioma: Outcomes of an Expanded Access Program

✍ Scribed by Pasi A. Jänne; Antoinette J. Wozniak; Chandra P. Belani; Mary-Louise Keohan; Helen J. Ross; Jonathan A. Polikoff; David M. Mintzer; Loretta Taylor; Joseph Ashland; Zhishen Ye; Matthew J. Monberg; Coleman K. Obasaju

Book ID: 115076592
Publisher: CIG Media Group, LP.
Year: 2005
Tongue: English
Weight: 512 KB
Volume: 7
Category: Article
ISSN: 1525-7304
DOI: 10.3816/clc.2005.n.020

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Single-arm, open label study of pemetrex

Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: Outcomes of an expanded access program

✍ Obasaju, Coleman K.; Ye, Zhishen; Wozniak, Antoinette J.; Belani, Chandra P.; Ke 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 330 KB

P-399 Pemetrexed alone or in combination

P-399 Pemetrexed alone or in combination with cisplatin in the treatment of patients with advanced malignant mesothelioma: An open-label trial of the National Cancer Institute of Egypt

✍ Gaafar, R.; Sallam, Y.; Khaled, H.; Rizk, G.; Emara, M.; Abou El-Kasem, F.; Ali 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 153 KB

497 An open-label, multicenter study of

497 An open-label, multicenter study of the efficacy and safety of peginterferon alfa-2A (40KD) (PEGASYS®), alone or in combination with ribavirin (COPEGUS®), in patients with HIV/HCV coinfection

✍ E. Ortega; A. Martin; C. Barros; K. Aguirrebengoa; J. Gonzalez; A. Garcia; R. Ru 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 62 KB

An open-label, multinational, multicente

An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer : The GC4 study

✍ Jaffer A. Ajani; J. Randolph Hecht; Linus Ho; Jackie Baker; Marga Oortgiesen; Ar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB

697 AN OPEN-LABEL, COMPARATIVE, MULTICEN

697 AN OPEN-LABEL, COMPARATIVE, MULTICENTRE STUDY OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN THE TREATMENT OF PATIENTS CHRONICALLY INFECTED WITH HCV/HBV OR HCV ALONE

✍ C.-J. Liu; W.-L. Chuang; C.-M. Lee; S.-S. Wu; L.-Y. Liao; H.-T. Kuo; Y.-C. Chao; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH